Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Blood

• Publication date

  2008-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1182/blood-2008-03-146001PMID 18559974
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thrombin-activable Fibrinolysis Inhibitor (TAFI) Zymogen Is an Active Carboxypeptidase*

  2007cited by this paper
• Announcing a TAFIa mutant with a 180‐fold increased half‐life and concomitantly a strongly increased antifibrinolytic potential

  2007cited by this paper
• Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.

  2007cited by this paper
• Recognizing protein–protein interfaces with empirical potentials and reduced amino acid alphabets

  2007cited by this paper
• Comparative evaluation of stable TAFIa variants: importance of α‐helix 9 and β‐sheet 11 for TAFIa (in)stability

  2007cited by this paper
• Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles.

  2007cited by this paper
• Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation.

  2006cited by this paper
• CAVER: a new tool to explore routes from protein clefts, pockets and cavities

  2006cited by this paper
• The intrinsic enzymatic activity of plasma procarboxypeptidase U (TAFI) can interfere with plasma carboxypeptidase N assays.

  2006cited by this paper
• Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down‐regulating fibrinolysis

  2006cited by this paper
• Generation of a Stable Activated Thrombin Activable Fibrinolysis Inhibitor Variant*

  2006cited by this paper
• Detailed molecular comparison between the inhibition mode of A/B-type carboxypeptidases in the zymogen state and by the endogenous inhibitor latexin

  2005cited by this paper
• Role of isoleucine residues 182 and 183 in thrombin‐activatable fibrinolysis inhibitor

  2005cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold‐dependent mechanism

  2004cited by this paper
• The Intrinsic Threshold of the Fibrinolytic System Is Modulated by Basic Carboxypeptidases, but the Magnitude of the Antifibrinolytic Effect of Activated Thrombin-activable Fibrinolysis Inhibitor Is Masked by Its Instability*

  2004cited by this paper
• Thrombin-activatable fibrinolysis inhibitor.

  2004cited by this paper
• Thrombin‐activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)

  2003cited by this paper
• Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis

  2003cited by this paper
• Stabilization Versus Inhibition of TAFIa by Competitive Inhibitors in Vitro *

  2003cited by this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and Fibrinolysis

  2003cited by this paper
• Structure and function in rhodopsin: High-level expression of rhodopsin with restricted and homogeneous N-glycosylation by a tetracycline-inducible N-acetylglucosaminyltransferase I-negative HEK293S stable mammalian cell line

  2002cited by this paper
• Two Naturally Occurring Variants of TAFI (Thr-325 and Ile-325) Differ Substantially with Respect to Thermal Stability and Antifibrinolytic Activity of the Enzyme*

  2002cited by this paper
• Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI).

  2002cited by this paper
• Human secretory signal peptide description by hidden Markov model and generation of a strong artificial signal peptide for secreted protein expression.

  2002cited by this paper
• High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.

  2002cited by this paper
• Pushing the boundaries of molecular replacement with maximum likelihood.

  2001cited by this paper
• The Crystal Structure of the Inhibitor-complexed Carboxypeptidase D Domain II and the Modeling of Regulatory Carboxypeptidases*

  2001cited by this paper
• Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).

  2001cited by this paper
• Roles of Thermal Instability and Proteolytic Cleavage in Regulation of Activated Thrombin-activable Fibrinolysis Inhibitor*

  2000cited by this paper
• Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage*

  2000cited by this paper
• The three‐dimensional structure of human procarboxypeptidase A2. Deciphering the basis of the inhibition, activation and intrinsic activity of the zymogen

  1997cited by this paper
• Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen.

  1994cited by this paper
• The CCP4 suite: programs for protein crystallography.

  1994cited by this paper
• PROCHECK: a program to check the stereochemical quality of protein structures

  1993cited by this paper
• Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants

  1993cited by this paper
• Crystallographic studies on apocarboxypeptidase A and the complex with glycyl-L-tyrosine.

  1983cited by this paper
• Electronic Reprint Biological Crystallography Maximum-likelihood Density Modification Using Pattern Recognition of Structural Motifs Pattern Recognition of Structural Motifs

  year unknowncited by this paper

• Detection of TAFI 1040C>T rs1926447 Gene Polymorphism in Type 2 Diabetes Mellitus Iraqi Patients

  2025cites this paper
• Novel Deep Sea Isoindole Alkaloid FGFC1 Exhibits Its Fibrinolytic Effects by Inhibiting Thrombin-Activatable Fibrinolysis Inhibitor

  2024cites this paper
• Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential

  2024cites this paper
• Fibrinolysis: an illustrated review

  2023cites this paper
• Selective Activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Attenuates Metastatic and Angiogenic Capabilities of Melanoma and Lung Carcinoma in vitro

  2023cites this paper
• Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics

  2021cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor (TAFI): An Updated Narrative Review

  2021influential citation
• Phosphinanes and Azaphosphinanes as Potent and Selective Inhibitors of Activated Thrombin-Activatable Fibrinolysis Inhibitor (TAFIa).

  2021cites this paper
• Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?

  2021cites this paper
• Structural insights into the modulatory role of the accessory protein WYL1 in the Type VI-D CRISPR-Cas system

  2019cites this paper
• Carboxypeptidase B2 and carboxypeptidase N in the crosstalk between coagulation, thrombosis, inflammation, and innate immunity

  2018cites this paper
• Multiple Architectures and Mechanisms of Latency in Metallopeptidase Zymogens.

  2018cites this paper
• TAFI: from activation to (self-)destruction

  2017cites this paper
• Changes in thrombin activatable fibrinolysis inhibitor and its role in normal pregnancy and pre-eclampsia

  2017cites this paper
• Blood Coagulation, Fibrinolysis and Cellular Haemostasis Binding characteristics of thrombin-activatable fibrinolysis inhibitor to streptococcal surface collagen-like proteins A and B

  2017cites this paper
• Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential

  2017cites this paper
• Physiological role of TAFI Attenuation of fibrinolysis

  2017cites this paper
• [Basic carboxypeptidases of blood: significance for coagulology].

  2016cites this paper
• Impact of Thrombomodulin and Thrombin-Activatable Fibrinolysis Inhibitor on the Anticoagulant and Profibrinolytic Effects of Rivaroxaban

  2016cites this paper
• Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis

  2016cites this paper
• Identification of a thrombomodulin interaction site on thrombin‐activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin

  2016cites this paper
• Stimulation of thrombin- and plasmin-mediated activation of thrombin-activatable fibrinolysis inhibitor by anionic molecules.

  2016cites this paper
• Regulation of the Activation and Function of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI)

  2016influential citation
• Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

  2016cites this paper
• Structure‐function relationships in thrombin‐activatable fibrinolysis inhibitor

  2016cites this paper
• Novel Small Molecule Inhibitors of Activated Thrombin Activatable Fibrinolysis Inhibitor (TAFIa) from Natural Product Anabaenopeptin.

  2015cites this paper
• Structural insights into the broad substrate specificity of carboxypeptidase T from Thermoactinomyces vulgaris

  2015cites this paper
• Data supporting the structural and functional characterization of Thrombin‐Activatable Fibrinolysis Inhibitor in breast cancer

  2015cites this paper
• An Analysis of MIF Structural Features that Control Functional Activation of CD74.

  2015cites this paper
• Generation of a stable thrombin‐activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation

  2015cites this paper
• Active but inoperable thrombin is accumulated in a plasma protein layer surrounding Streptococcus pyogenes

  2015cites this paper
• New clues regarding the mysterious mechanism of activated thrombin‐activatable fibrinolysis inhibitor self‐destruction

  2015cites this paper
• Basic mechanisms and regulation of fibrinolysis

  2015cites this paper
• Selective modulation of thrombin‐activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin‐thrombomodulin complex using TAFI‐derived peptides

  2015cites this paper
• The role of Thrombin Activatable Fibrinolysis Inhibitor in Abdominal Aortic Aneurysms

  2015cites this paper
• TAFIa Instability and its Role in Breast Cancer Metastasis

  2015cites this paper
• TAFIa is a Novel Inhibitor of Tumour Angiogenesis in Breast Cancer

  2015influential citation
• Characterization of TAFI Activation by the Thrombin-Thrombomodulin Complex

  2015influential citation
• Carboxyterminal protein processing in health and disease: key actors and emerging technologies.

  2014cites this paper
• Identification of a novel, nanobody‐induced, mechanism of TAFI inactivation and its in vivo application

  2014cites this paper
• Model Systems to Explore CPB2 Pre-mRNA Splicing

  2014cites this paper
• In vitro and in vivo characterisation of the profibrinolytic effect of an inhibitory anti-rat TAFI nanobody

  2014cites this paper
• Structure and function of thrombin activatable fibrinolysis inhibitor

  2014cites this paper
• A role for arginine‐12 in thrombin–thrombomodulin‐mediated activation of thrombin‐activatable fibrinolysis inhibitor

  2014cites this paper
• Thrombin Activatable Fibrinolysis Inhibitor: A Putative Target to Enhance Fibrinolysis

  2013cites this paper
• Metallocarboxypeptidases and their inhibitors: recent developments in biomedically relevant protein and organic ligands.

  2013cites this paper
• Insights into thrombin activatable fibrinolysis inhibitor function and regulation

  2013cites this paper
• Chapter 295 – Carboxypeptidase U

  2013cites this paper
• The mRNA encoding TAFI is alternatively spliced in different cell types and produces intracellular forms of the protein lacking TAFIa activity

  2013cites this paper
• Chapter 296 – Carboxypeptidase B

  2013cites this paper
• Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

  2012cites this paper
• Design and characterization of a selenium-containing inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa), a zinc-containing metalloprotease.

  2012cites this paper
• Microneme Protein 5 Regulates the Activity of Toxoplasma Subtilisin 1 by Mimicking a Subtilisin Prodomain*

  2012cites this paper
• Polución aérea y estado protrombótico

  2012cites this paper
• Role of Heparin Binding in Plasmin-mediated Activation of TAFI and Thermal Stability of TAFIa

  2012cites this paper
• Regulation of the Gene Encoding Thrombin-Activable Fibrinolysis Inhibitor in Non-Hepatic Cells

  2011cites this paper
• Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms

  2011cites this paper
• Kinetics of Activated Thrombin-activatable Fibrinolysis Inhibitor (TAFIa)-catalyzed Cleavage of C-terminal Lysine Residues of Fibrin Degradation Products and Removal of Plasminogen-binding Sites*

  2011cites this paper
• Factor XI deficiency : a study of clinical, laboratory and molecular modifiers of bleeding phenotype

  2011cites this paper
• Therapy of Polycythemia Vera and Essential Thrombocythemia

  2011cites this paper
• An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.

  2011influential citation
• Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis.

  2011cites this paper
• Thrombin activatable fibrinolysis inhibitor

  2011cites this paper
• How to manage thrombosis in myeloproliferative neoplasms

  2011cites this paper
• Thrombin-activatable fibrinolysis inhibitor and bacterial infections

  2011cites this paper
• Structure–Function Analysis of the Short Splicing Variant Carboxypeptidase Encoded by Drosophila melanogaster silver

  2010cites this paper
• Substrate Specificity of Human Carboxypeptidase A6*

  2010cites this paper
• Analysis of a new crystal form of procarboxypeptidase B: further insights into the catalytic mechanism.

  2010cites this paper
• Polymorphisms in the CPB2 gene are maintained by balancing selection and result in haplotype-preferential splicing of exon 7.

  2010cites this paper
• Flexibility of the Thrombin-activatable Fibrinolysis Inhibitor Pro-domain Enables Productive Binding of Protein Substrates*

  2010cites this paper
• The role of the fibrinolytic system in arterial and venous thrombosis

  2010cites this paper
• The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome

  2010cites this paper
• Insights into the molecular inactivation mechanism of human activated thrombin‐activatable fibrinolysis inhibitor

  2010cites this paper
• Thrombin‐activatable fibrinolysis inhibitor is degraded by Salmonella enterica and Yersinia pestis

  2010cites this paper
• Progress in metallocarboxypeptidases and their small molecular weight inhibitors.

  2010cites this paper
• 1. New global fibrinolysis assays and their clinical application

  2009cites this paper
• Secretion and Antifibrinolytic Function of TAFI from Human Platelets

  2009cites this paper
• Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)

  2009cites this paper
• anaphylatoxins Staphylococcal SSL5 inhibits leukocyte activation by chemokines and

  2009cites this paper
• Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men

  2009cites this paper
• Functional Characterization of TAFI mutants Resistant to Activation by Thrombin, Thrombin- Thrombomodulin or Plasmin

  2009cites this paper
• New insights into the molecular mechanisms of the fibrinolytic system

  2009cites this paper
• Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms

  2009cites this paper
• The Roles of Selected Arginine and Lysine Residues of TAFI (Pro-CPU) in Its Activation to TAFIa by the Thrombin-Thrombomodulin Complex*

  2009cites this paper
• Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?

  2009cites this paper
• The activation peptide of thrombin‐activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme?

  2009cites this paper
• Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins.

  2009cites this paper
• Carboxypeptidase M: Multiple alliances and unknown partners.

  2009cites this paper
• Functional analysis of mutant variants of thrombin‐activatable fibrinolysis inhibitor resistant to activation by thrombin or plasmin

  2009cites this paper